Axanum is a fixed-dose combination containing low-dose acetylsalicylic acid and the active ingredient of Nexium for the prevention of cardio- and cerebrovascular events in patients requiring continuous low-dose ASA treatment and at risk for developing ASA associated gastric and/or duodenal ulcers. The company is currently in discussions with the FDA regarding next steps for the drug, according to the release.
The FDA also rejected a supplemental new drug for Nexium, which was submitted for the risk reduction of low-dose aspirin-associated peptic ulcers.
Read the release on AstraZeneca’s CRLs for Axanum and Nexium.
At the Becker's 23rd Annual Spine, Orthopedic and Pain Management-Driven ASC + The Future of Spine Conference, taking place June 11-13 in Chicago, spine surgeons, orthopedic leaders and ASC executives will come together to explore minimally invasive techniques, ASC growth strategies and innovations shaping the future of outpatient spine care. Apply for complimentary registration now.
